
Tempus AI Inc (NASDAQ:TEM) shares are trading higher Monday morning after the company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.
What To Know: Per the company, this in vitro diagnostic tool utilizes next-generation sequencing to analyze RNA from tumor samples, aiding in the identification of molecular pathways and networks integral to disease progression.